A subscription to JoVE is required to view this content. Sign in or start your free trial.
This protocol describes a technique for the analysis of respiratory supercomplexes when only small amounts of samples are available.
Over the last decades, the evidence accumulated about the existence of respiratory supercomplexes (SCs) has changed our understanding of the mitochondrial electron transport chain organization, giving rise to the proposal of the "plasticity model." This model postulates the coexistence of different proportions of SCs and complexes depending on the tissue or the cellular metabolic status. The dynamic nature of the assembly in SCs would allow cells to optimize the use of available fuels and the efficiency of electron transfer, minimizing reactive oxygen species generation and favoring the ability of cells to adapt to environmental changes.
More recently, abnormalities in SC assembly have been reported in different diseases such as neurodegenerative disorders (Alzheimer's and Parkinson's disease), Barth Syndrome, Leigh syndrome, or cancer. The role of SC assembly alterations in disease progression still needs to be confirmed. Nevertheless, the availability of enough amounts of samples to determine the SC assembly status is often a challenge. This happens with biopsy or tissue samples that are small or have to be divided for multiple analyses, with cell cultures that have slow growth or come from microfluidic devices, with some primary cultures or rare cells, or when the effect of particular costly treatments has to be analyzed (with nanoparticles, very expensive compounds, etc.). In these cases, an efficient and easy-to-apply method is required. This paper presents a method adapted to obtain enriched mitochondrial fractions from small amounts of cells or tissues to analyze the structure and function of mitochondrial SCs by native electrophoresis followed by in-gel activity assays or western blot.
Supercomplexes (SCs) are supramolecular associations between individual respiratory chain complexes1,2. Since the initial identification of SCs and the description of their composition by the group of Schägger2,3, later confirmed by other groups, it was established that they contain respiratory complexes I, III, and IV (CI, CIII, and CIV, respectively) in different stoichiometries. Two main populations of SCs can be defined, those containing CI (and either CIII alone or CIII and CIV) and with very high molecular weight (MW, starting ~1.5 MDa for t....
NOTE: The composition of all culture media and buffers is specified in Table 1 and details related to all materials and reagents used in this protocol are listed in the Table of Materials.
1. Mitochondria isolation from cell culture
NOTE: The minimum volume of cells assayed has been ~30-50 µL of packed cells (step 1.4). This can correspond approximately to at least two or three 100 mm cell culture plates or to on.......
The yields of mitochondria obtained following the above-described protocols vary depending on several factors such as the cell line or tissue type, the nature of the samples (i.e., if fresh or frozen tissues are used), or the efficiency of the homogenization process. Expected yields of mitochondria from different cell lines and tissues are collected in Table 2. Once the mitochondrial fractions have been obtained, the next step is the analysis of respiratory SCs pattern, which is performed after the crude.......
The methodological adaptations introduced in the protocols described here are intended to avoid losses and increase the yield while maintaining mitochondrial complex activities (which is crucial when the availability of enough amounts of samples is compromised) and reproduce the tissue's or cell line's expected pattern of SCs (see Figure 2C). With this purpose and since a high mitochondrial purity is not required to properly detect the SCs, the number of steps, times, and volume.......
This work was supported by grant number "PGC2018-095795-B-I00" from Ministerio de Ciencia e Innovación (https://ciencia.sede.gob.es/) and by grants “Grupo de Referencia: E35_17R” and grant number “LMP220_21” from Diputación General de Aragón (DGA) (https://www.aragon.es/) to PF-S and RM-L.
....Name | Company | Catalog Number | Comments |
Acetic acid | PanReac | 131008 | |
Aminocaproic acid | Fluka Analytical | 7260 | |
ATP | Sigma-Aldrich | A2383 | |
Bis Tris | Acrons Organics | 327721000 | |
Bradford assay | Biorad | 5000002 | |
Coomassie Blue G-250 | Serva | 17524 | |
Coomassie Blue R-250 | Merck | 1125530025 | |
Cytochrome c | Sigma-Aldrich | C2506 | |
Diamino benzidine (DAB) | Sigma-Aldrich | D5637 | |
Digitonin | Sigma-Aldrich | D5628 | |
EDTA | PanReac | 131669 | |
EGTA | Sigma-Aldrich | E3889 | |
Fatty acids free BSA | Roche | 10775835001 | |
Glycine | PanReac | A1067 | |
Homogenizer Teflon pestle | Deltalab | 196102 | |
Imidazole | Sigma-Aldrich | I2399 | |
K2HPO4 | PanReac | 121512 | |
KH2PO4 | PanReac | 121509 | |
Mannitol | Sigma-Aldrich | M4125 | |
Methanol | Labkem | MTOL-P0P | |
MgSO4 | PanReac | 131404 | |
Mini Trans-Blot Cell | BioRad | 1703930 | |
MOPS | Sigma-Aldrich | M1254 | |
MTCO1 Monoclonal Antibody | Invitrogen | 459600 | |
NaCl | Sigma-Aldrich | S9888 | |
NADH | Roche | 10107735001 | |
NativePAGE 3 to 12% Mini Protein Gels | Invitrogen | BN1001BOX | |
NativePAGE Cathode Buffer Additive (20x) | Invitrogen | BN2002 | |
NativePAGE Running Buffer (20x) | Invitrogen | BN2001 | |
NDUFA9 Monoclonal Antibody | Invitrogen | 459100 | |
Nitroblue tetrazolium salt (NBT) | Sigma-Aldrich | N6876 | |
Pb(NO3)2 | Sigma-Aldrich | 228621 | |
PDVF Membrane | Amersham | 10600023 | |
Phenazine methasulfate (PMS) | Sigma-Aldrich | P9625 | |
Pierce ECL Substrate | Thermo Scientific | 32106 | |
PMSF | Merck | PMSF-RO | |
SDHA Monoclonal Antibody | Invitrogen | 459200 | |
Sodium succinate | Sigma-Aldrich | S2378 | |
Streptomycin/penicillin | PAN biotech | P06-07100 | |
Sucrose | Sigma-Aldrich | S3089 | |
Tris | PanReac | A2264 | |
UQCRC1 Monoclonal Antibody | Invitrogen | 459140 | |
XCell SureLock Mini-Cell | Invitrogen | EI0001 |
This article has been published
Video Coming Soon
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved